Research Paper

Core Innovation

This paper introduces DeepTokenEEG, a novel lightweight model using spatial and temporal tokenizers to capture Alzheimer's biomarkers in EEG data. It achieves higher accuracy with fewer parameters compared to existing deep learning methods, enabling efficient and scalable Alzheimer's classification.

Why It Matters

Alzheimer's early detection is critical for timely intervention but current EEG-based methods face challenges in accuracy and complexity. DeepTokenEEG offers a more accurate, efficient, and accessible diagnostic tool that can scale across healthcare settings, reducing reliance on expert interpretation and enabling broader screening.

Potential Customers & Pain Points

• Hospitals – Need accurate fast Alzheimer's diagnosis
• Neurology clinics – Require cost-effective screening tools
• Research institutions – Need reliable EEG analysis models
• Elder care facilities – Seek early detection solutions to improve patient outcomes

Business Model

Licensing the DeepTokenEEG model to medical device manufacturers and healthcare providers; offering SaaS EEG analysis platform for Alzheimer's screening; partnerships with hospitals for pilot deployments.

Competitive Landscape

• NeuroSky
• Emotiv
• BrainScope
• Cognionics

Implementation Challenges

• Regulatory approval for clinical diagnostic use
• Integration with existing hospital EEG systems
• Data privacy and patient consent management
• Clinical validation across diverse populations

Validation Strategy

• Conduct clinical trials to validate diagnostic accuracy in diverse patient cohorts
• Collaborate with hospitals for real-world pilot testing
• Obtain regulatory certifications for medical use
• Iterate model based on clinical feedback and new EEG datasets